- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01837563
Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer
September 28, 2015 updated by: Dartmouth-Hitchcock Medical Center
The purpose of this study is to determine whether four new alternative imaging methods can be used to follow the response of breast cancer to the treatment patients are being given.
These methods produce an image of the inside of the breast so that doctors can better decide whether breast cancer is responding to therapy.
An important part of the study is to examine the same person with all methods in order to directly compare results.
The four methods are: MRI Elasticity Imaging (abbreviated MRE), Electrical Impedance Spectroscopy (abbreviated EIS), Microwave Imaging and Spectroscopy (abbreviated MIS), Near Infrared Spectroscopy (abbreviated NIR).
In addition to the experimental imaging methods, patients may also undergo a contrast-enhanced MRI, and/or additional mammography, which will help researchers compare the experimental methods.
These additional examinations are accepted diagnostic procedures; they are not experimental.
Some participants will have one or both of these additional examinations if clinically indicated.
Study Overview
Status
Terminated
Conditions
Study Type
Observational
Enrollment (Actual)
36
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth-Hitchcock Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Women with locally-advanced breast cancer, with or without metastatic disease, meeting inclusion criteria (and giving informed consent for participation) receiving systemic therapy at DHMC will be enrolled.
Breast size and epithelial integrity of the skin surface can limit the ability to deliver effective imaging exams, adn these individual characteristics need be determined in each individual patient.
Women with pacemakers or other implanted electronic devices will not be allowed into the study because of potential for electrical interference with proper operation during an imaging session.
Description
Inclusion Criteria:
- Locally advanced breast cancer, with or without metastatic disease
- Patient to receive systemic therapy
- Breast size and epithelial integrity adequate to allow alternate imaging exams.
- Patient able to provide written informed consent.
- No serious associated psychiatric illness
- Age ≥ 18 years old
Exclusion Criteria:
- Cardiac pacemaker
- Any implanted electronic device
- Severe claustrophobia
- Allergy to the MRI contrast agent gadolinium
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response
Time Frame: at baseline, at conclusion of treatment (up to 6 months)
|
Correlate changes in each imaging modality with objective response to therapy, as defined by conventional criteria (clinical exam and conventional imaging).
|
at baseline, at conclusion of treatment (up to 6 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (Actual)
September 1, 2015
Study Completion (Actual)
September 1, 2015
Study Registration Dates
First Submitted
April 16, 2013
First Submitted That Met QC Criteria
April 18, 2013
First Posted (Estimate)
April 23, 2013
Study Record Updates
Last Update Posted (Estimate)
September 30, 2015
Last Update Submitted That Met QC Criteria
September 28, 2015
Last Verified
September 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D0605
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Breast Cancer
-
The First Affiliated Hospital of Xiamen UniversityNot yet recruitingLocally Advanced Breast Cancer (LABC)
-
Beijing Bio-Targeting Therapeutics Technology Co...Withdrawn
-
Introgen TherapeuticsCompletedLocally Advanced Breast Cancer (LABC)United States
-
Universitas AirlanggaNot yet recruitingBreast Cancer | Breast Neoplasm Female | Locally Advanced Breast Cancer | Locally Advanced Breast Cancer (LABC)
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingEarly-stage or Locally Advanced HER2-positive Breast CancerChina
-
Indonesia UniversityNot yet recruitingPrehabilitation | Postoperative Inflammation | Locally Advanced Breast Cancer (LABC)Indonesia
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast CarcinomaUnited States
-
Abramson Cancer Center at Penn MedicineCompletedAdvanced Breast Cancer | Metastatic Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Locally Advanced Breast CancerUnited States
-
Consorzio OncotechRecruitingMetastatic Breast Cancer | Locally Advanced Breast CancerItaly
-
Carrick Therapeutics LimitedPfizerCompletedBreast Cancer | Metastatic Breast Cancer | Locally Advanced Breast CancerHungary, Spain, United States, Mexico, Turkey (Türkiye)